| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Rene Rodriguez | Q37836712 |
| Pablo Menendez | Q38329307 | ||
| Javier Garcia-castro | Q43111748 | ||
| P2093 | author name string | J A Pérez-Simón | |
| J Madrenas | |||
| C Trigueros | |||
| P2860 | cites work | Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway | Q24298295 |
| Molecular mechanisms for adaptive tolerance and other T cell anergy models | Q24671646 | ||
| Adult mesenchymal stem cells and cell-based tissue engineering | Q24796160 | ||
| Stem cell niche: structure and function | Q28276131 | ||
| Human mesenchymal stem cells modulate allogeneic immune cell responses | Q28288692 | ||
| Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche | Q28505006 | ||
| Mesenchymal stem cells within tumour stroma promote breast cancer metastasis | Q29614303 | ||
| Identification of the haematopoietic stem cell niche and control of the niche size | Q29615008 | ||
| Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study | Q29617267 | ||
| Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells | Q29618766 | ||
| Chondrogenic potential of human synovial mesenchymal stem cells in alginate. | Q50468942 | ||
| Potential risks of bone marrow cell transplantation into infarcted hearts. | Q50685139 | ||
| Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). | Q51953623 | ||
| Preimplantation-stage stem cells induce long-term allogeneic graft acceptance without supplementary host conditioning | Q45883050 | ||
| The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. | Q46010474 | ||
| Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease | Q46843859 | ||
| Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. | Q46845322 | ||
| Autologous bone marrow stromal cells loaded onto porous hydroxyapatite ceramic accelerate bone repair in critical-size defects of sheep long bones | Q47250977 | ||
| Effects of Wnt signaling on proliferation and differentiation of human mesenchymal stem cells | Q47424802 | ||
| Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors | Q47605320 | ||
| Susceptibility and resistance to antigen-induced apoptosis in the thymus of transgenic mice | Q48032387 | ||
| Wnt signaling regulates the invasion capacity of human mesenchymal stem cells | Q48088586 | ||
| Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas | Q48926056 | ||
| Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion | Q49047090 | ||
| Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment | Q29620053 | ||
| Graft-versus-host disease: a surge of developments | Q33290423 | ||
| Molecular characterization of spontaneous mesenchymal stem cell transformation | Q33312958 | ||
| Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing | Q33326623 | ||
| Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta | Q33855709 | ||
| Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy | Q33861711 | ||
| Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells | Q33992270 | ||
| Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone | Q34066339 | ||
| Characterization of the expression of MHC proteins in human embryonic stem cells | Q34076010 | ||
| CD3+CD4-CD8- alphabeta-TCR+ T cell as immune regulatory cell | Q34340915 | ||
| Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. | Q34569888 | ||
| SSEA-4 identifies mesenchymal stem cells from bone marrow | Q34576375 | ||
| Differentiation of human mesenchymal stem cells and articular chondrocytes: analysis of chondrogenic potential and expression pattern of differentiation-related transcription factors. | Q34577607 | ||
| The Wnt signal transduction pathway in stem cells and cancer cells: influence on cellular invasion. | Q34688333 | ||
| Multiple tumor types may originate from bone marrow-derived cells | Q35082670 | ||
| Pretransplant blood transfusions revisited: a role for CD(4+) regulatory T cells? | Q35630658 | ||
| Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase | Q35677647 | ||
| Clinical trials with adult stem/progenitor cells for tissue repair: let's not overlook some essential precautions | Q35751008 | ||
| Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting | Q35849125 | ||
| Understanding mesenchymal cancer: the liposarcoma-associated FUS-DDIT3 fusion gene as a model | Q36096576 | ||
| Genetic manipulation of human embryonic stem cells: a system to study early human development and potential therapeutic applications | Q36230369 | ||
| Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma | Q36238078 | ||
| Major histocompatibility complex class II-positive cortical epithelium mediates the selection of CD4(+)25(+) immunoregulatory T cells | Q36369536 | ||
| The efficiency of CD4 recruitment to ligand-engaged TCR controls the agonist/partial agonist properties of peptide-MHC molecule ligands | Q36376752 | ||
| Molecular regulation of T-cell anergy | Q36466372 | ||
| A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. | Q36512275 | ||
| Primer: mechanisms of immunologic tolerance | Q36577410 | ||
| Bone marrow mesenchymal stem cells are abnormal in multiple myeloma | Q36593549 | ||
| Human embryonic stem cells: potential tool for achieving immunotolerance? | Q36672114 | ||
| Cord-blood mesenchymal stem cells and tissue engineering | Q36712812 | ||
| Wnt/beta-catenin signaling in cancer stemness and malignant behavior | Q36738603 | ||
| New twists of T cell fate: control of T cell activation and tolerance by TGF-beta and NFAT. | Q36791441 | ||
| Advances in cell-based therapy for structural heart disease | Q36820216 | ||
| B-cell anergy: from transgenic models to naturally occurring anergic B cells? | Q36887132 | ||
| Tolerance induction in presensitized bone marrow recipients by veto CTLs: effective deletion of host anti-donor memory effector cells. | Q51970080 | ||
| Homeostatic expansion permits T cells to re-enter the thymus and deliver antigen in a tolerogenic fashion. | Q51973805 | ||
| Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. | Q52170394 | ||
| Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. | Q53328521 | ||
| Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. | Q53343855 | ||
| Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. | Q53352599 | ||
| Spontaneous human adult stem cell transformation. | Q53358878 | ||
| EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. | Q53487773 | ||
| Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. | Q54073234 | ||
| Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. | Q54308518 | ||
| Zebrafish fins as a model system for skeletal human studies. | Q55048845 | ||
| CTLA-4 regulates induction of anergy in vivo | Q56905417 | ||
| Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents | Q58828469 | ||
| Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells | Q59102107 | ||
| Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells | Q61645531 | ||
| Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease | Q63197317 | ||
| Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents | Q64379193 | ||
| Osteogenesis in transplants of bone marrow cells | Q71202383 | ||
| Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation | Q73117300 | ||
| Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy | Q73358706 | ||
| Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression | Q73977252 | ||
| Pre-transplant blood transfusion and renal allograft outcome: a report of the North American Pediatric Renal Transplant Cooperative Study | Q74619623 | ||
| T-cell anergy and altered T-cell receptor signaling: effects on autoimmune disease | Q77454764 | ||
| Thymic re-entry of mature activated T cells and increased negative selection in vascularized allograft recipients | Q77737333 | ||
| Influence of the different CD34+ and CD34- cell subsets infused on clinical outcome after non-myeloablative allogeneic peripheral blood transplantation from human leucocyte antigen-identical sibling donors | Q78311697 | ||
| Nonhematopoietic/endothelial SSEA-1+ cells define the most primitive progenitors in the adult murine bone marrow mesenchymal compartment | Q79143613 | ||
| HLA expression and immunologic propertiesof differentiated and undifferentiated mesenchymal stem cells | Q79149793 | ||
| Presence of mesenchymal stem cells in human bone marrow after exposure to chemotherapy: evidence of resistance to apoptosis induction | Q80165361 | ||
| Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells | Q80413361 | ||
| The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study | Q80471824 | ||
| Human mesenchymal stem cell transformation is associated with a mesenchymal-epithelial transition | Q80507318 | ||
| Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon | Q80568647 | ||
| Bone marrow stromal cell-derived Wnt signals as a potential underlying mechanism for cyclin D1 deregulation in multiple myeloma lacking t(11;14)(q13;q32) | Q80614725 | ||
| Gastric cancer originating from bone marrow-derived cells | Q81067451 | ||
| Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling | Q81299785 | ||
| Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance | Q81308407 | ||
| Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients | Q81676895 | ||
| Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients | Q82242208 | ||
| Bone marrow mesenchymal stem cells chimerism after allogeneic hematopoietic transplantation | Q82264274 | ||
| Apoptosis during negative selection of autoreactive thymocytes | Q36893056 | ||
| Immune tolerance: mechanisms and application in clinical transplantation | Q36909564 | ||
| Human stem cells for CNS repair. | Q36954408 | ||
| Immunomodulation by mesenchymal stem cells and clinical experience | Q36975987 | ||
| Dendritic cell therapy for tolerance induction to stem cell transplants. | Q37066434 | ||
| Cancer stem cells--old concepts, new insights. | Q37079713 | ||
| The Foxp3+ regulatory T cell: a jack of all trades, master of regulation | Q37088900 | ||
| Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells | Q37134013 | ||
| The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance | Q37152481 | ||
| Stem cell regeneration of degenerated intervertebral discs: current status | Q37161478 | ||
| Technology insight: adult mesenchymal stem cells for osteoarthritis therapy | Q37163015 | ||
| Mesenchymal stromal cells: a novel treatment option for steroid-induced avascular osteonecrosis. | Q37169425 | ||
| Long-term in vitro expansion alters the biology of adult mesenchymal stem cells | Q37269767 | ||
| Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model | Q37310677 | ||
| Interleukin 2 production, not the pattern of early T-cell antigen receptor-dependent tyrosine phosphorylation, controls anergy induction by both agonists and partial agonists | Q37362068 | ||
| Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma | Q38507328 | ||
| Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model | Q39998770 | ||
| The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo | Q40039805 | ||
| Spontaneous expression of embryonic factors and p53 point mutations in aged mesenchymal stem cells: a model of age-related tumorigenesis in mice | Q40050583 | ||
| Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice | Q40052794 | ||
| Electron microscopy reveals the presence of viruses in mouse embryonic fibroblasts but neither in human embryonic fibroblasts nor in human mesenchymal cells used for hESC maintenance: toward an implementation of microbiological quality assurance pro | Q40128166 | ||
| In vitro transformation of mesenchymal stem cells by oncogenic H-rasVal12. | Q40195027 | ||
| Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells | Q40216419 | ||
| Sarcoma derived from cultured mesenchymal stem cells | Q40220522 | ||
| T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha | Q40222415 | ||
| Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. | Q40348177 | ||
| Adult human mesenchymal stem cell as a target for neoplastic transformation | Q40563067 | ||
| Gene-enhanced tissue engineering: applications for bone healing using cultured periosteal cells transduced retrovirally with the BMP-7 gene. | Q40952287 | ||
| Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. | Q41675626 | ||
| Calcium phosphate surfaces promote osteogenic differentiation of mesenchymal stem cells | Q41969492 | ||
| Immunosuppressive therapy and tolerance of organ allografts | Q42365619 | ||
| Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation | Q44746492 | ||
| Mesenchymal stem cells for graft-versus-host disease: a double edged sword? | Q44786836 | ||
| Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease | Q45861396 | ||
| Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate | Q45863683 | ||
| Gene therapy and stem cell therapy for cardiovascular diseases today: a model for translational research | Q45865166 | ||
| Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors | Q45869203 | ||
| Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness | Q45879145 | ||
| P433 | issue | 6B | |
| P921 | main subject | mesenchymal stem cell | Q1922379 |
| cell | Q7868 | ||
| biomedical investigative technique | Q66648976 | ||
| P304 | page(s) | 2552-2565 | |
| P577 | publication date | 2008-12-01 | |
| P1433 | published in | Journal of Cellular and Molecular Medicine | Q1524063 |
| P1476 | title | Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool | |
| P478 | volume | 12 |
| Q38716821 | A novel rat fibrosarcoma cell line from transformed bone marrow-derived mesenchymal stem cells with maintained in vitro and in vivo stemness properties |
| Q38743388 | Achieving the Promise of Therapeutic Extracellular Vesicles: The Devil is in Details of Therapeutic Loading |
| Q38344723 | Allogeneic cardiac stem cell administration for acute myocardial infarction |
| Q39032517 | Bone environment is essential for osteosarcoma development from transformed mesenchymal stem cells |
| Q42066221 | Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene |
| Q33828556 | Bone marrow mesenchymal stem cells from patients with aplastic anemia maintain functional and immune properties and do not contribute to the pathogenesis of the disease. |
| Q61803946 | Bone marrow mesenchymal stem/stromal cells from risk-stratified acute myeloid leukemia patients are anti-inflammatory in preclinical models of hematopoietic reconstitution and severe colitis |
| Q50668745 | C-kit+ cardiac progenitors exhibit mesenchymal markers and preferential cardiovascular commitment. |
| Q33873772 | CD34(+) cell selection using small-volume marrow aspirates: a platform for novel cell therapies and regenerative medicine |
| Q91876849 | CDKN2B upregulation prevents teratoma formation in multipotent fibromodulin-reprogrammed cells |
| Q37986552 | Cardiac cell therapy: boosting mesenchymal stem cells effects |
| Q35277772 | Cell membrane damage is involved in the impaired survival of bone marrow stem cells by oxidized low-density lipoprotein |
| Q38136188 | Cellular kinetics of perivascular MSC precursors. |
| Q38314852 | Concise Review: Mesenchymal Stem Cells Ameliorate Tissue Injury via Secretion of Tumor Necrosis Factor-α Stimulated Protein/Gene 6. |
| Q33795203 | Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes |
| Q35091467 | Differentiation and regeneration potential of mesenchymal progenitor cells derived from traumatized muscle tissue |
| Q36648040 | Differentiation of human adipose-derived stem cells into fat involves reactive oxygen species and Forkhead box O1 mediated upregulation of antioxidant enzymes |
| Q36956196 | Effects of human bone marrow mesenchymal stem cells on burn injury healing in a mouse model |
| Q39721057 | Endoplasmic reticulum stress signals in defined human embryonic stem cell lines and culture conditions. |
| Q39512034 | Enrichment of human ESC-derived multipotent mesenchymal stem cells with immunosuppressive and anti-inflammatory properties capable to protect against experimental inflammatory bowel disease. |
| Q39128691 | Expression of FUS-CHOP fusion protein in immortalized/transformed human mesenchymal stem cells drives mixoid liposarcoma formation. |
| Q39889922 | Expression of Pdx1 mediates differentiation from mesenchymal stem cells into insulin-producing cells |
| Q38333689 | FUS-CHOP fusion protein expression coupled to p53 deficiency induces liposarcoma in mouse but not in human adipose-derived mesenchymal stem/stromal cells. |
| Q34308614 | Fabrication and biological evaluation of uniform extracellular matrix coatings on discontinuous photolithography generated micropallet arrays. |
| Q46499291 | Feeder-free maintenance of hESCs in mesenchymal stem cell-conditioned media: distinct requirements for TGF-beta and IGF-II. |
| Q42151228 | Genetic modification of human mesenchymal stem cells helps to reduce adiposity and improve glucose tolerance in an obese diabetic mouse model |
| Q34171422 | Global transcriptional analysis for biomarker discovery and validation in cellular therapies |
| Q37691004 | Hemato-vascular origins of endothelial progenitor cells? |
| Q38943709 | Human bone marrow stromal cells lose immunosuppressive and anti-inflammatory properties upon oncogenic transformation |
| Q39804300 | Human embryonic stem cell-derived mesenchymal stromal cells ameliorate collagen-induced arthritis by inducing host-derived indoleamine 2,3 dioxygenase |
| Q30498118 | Hyaluronidase recruits mesenchymal-like cells to the lung and ameliorates fibrosis |
| Q37448184 | Implantation of placenta-derived mesenchymal stem cells accelerates murine dermal wound closure through immunomodulation |
| Q91703857 | Induced Pluripotent Stem Cell-Derived Mesenchymal Stromal Cells Are Functionally and Genetically Different From Bone Marrow-Derived Mesenchymal Stromal Cells |
| Q46005037 | Influence of hypoxia on the stemness of umbilical cord matrix-derived mesenchymal stem cells cultured on chitosan films. |
| Q104471893 | Intracellular role of IL-6 in mesenchymal stromal cell immunosuppression and proliferation |
| Q34010930 | Isolation and characterization of mesenchymal progenitor cells from human orbital adipose tissue |
| Q33876656 | Labeling and tracing of bone marrow mesenchymal stem cells for tendon-to-bone tunnel healing |
| Q39235167 | Mesenchymal Stem Cells Increase Hippocampal Neurogenesis and Neuronal Differentiation by Enhancing the Wnt Signaling Pathway in an Alzheimer's Disease Model. |
| Q35787951 | Mesenchymal Stromal Cells for Sphincter Regeneration: Role of Laminin Isoforms upon Myogenic Differentiation. |
| Q38543181 | Mesenchymal stem cell-based gene therapy: A promising therapeutic strategy |
| Q42223399 | Mesenchymal stem cells regulate airway contractile tissue remodeling in murine experimental asthma. |
| Q36883559 | Mesenchymal stem cells, aging and regenerative medicine |
| Q42133000 | Mesenchymal stem cells: From bench to bedside |
| Q38780560 | Mesenchymal stem cells: From stem cells to sarcomas |
| Q37935534 | Modeling sarcomagenesis using multipotent mesenchymal stem cells |
| Q39644238 | Myogenic differentiation of mesenchymal stem cells co-cultured with primary myoblasts |
| Q35023903 | New insights in osteogenic differentiation revealed by mass spectrometric assessment of phosphorylated substrates in murine skin mesenchymal cells |
| Q28251469 | Pathogenesis of tendinopathies: inflammation or degeneration? |
| Q45834926 | Platelet-derived growth factor BB gene-released scaffolds: biosynthesis and characterization. |
| Q34479398 | Potential therapeutic applications of muscle-derived mesenchymal stem and progenitor cells |
| Q37294819 | Proliferation and differentiation potential of human adipose-derived mesenchymal stem cells isolated from elderly patients with osteoporotic fractures |
| Q41296731 | Promoting effect of small molecules in cardiomyogenic and neurogenic differentiation of rat bone marrow-derived mesenchymal stem cells |
| Q39721075 | Reduced oxygen stress promotes propagation of murine postnatal enteric neural progenitors in vitro |
| Q90323842 | Robustness of Catalytically Dead Cas9 Activators in Human Pluripotent and Mesenchymal Stem Cells |
| Q38132245 | Senescence bypass in mesenchymal stem cells: a potential pathogenesis and implications of pro-senescence therapy in sarcomas |
| Q54348216 | Senescence of bone marrow mesenchymal stromal cells is accompanied by activation of p53/p21 pathway in myelodysplastic syndromes. |
| Q35840661 | Stem cell applications in military medicine |
| Q42366723 | Stem cell therapy for nerve injury. |
| Q34560827 | Stem/progenitor cells from inflamed human dental pulp retain tissue regeneration potential |
| Q28548012 | The Toll-Like Receptor 5 Agonist Entolimod Mitigates Lethal Acute Radiation Syndrome in Non-Human Primates |
| Q50545712 | The differentiation stage of p53-Rb-deficient bone marrow mesenchymal stem cells imposes the phenotype of in vivo sarcoma development. |
| Q37790311 | The potential of adipose stem cells in regenerative medicine. |
| Q37043780 | The role of mesenchymal stem/progenitor cells in sarcoma: update and dispute |
| Q34102794 | The spectrum of celiac disease: epidemiology, clinical aspects and treatment |
| Q39160337 | The use of hypoxic cultured mesenchymal stem cell for oncolytic virus therapy |
| Q89769517 | Therapeutic Mesenchymal Stromal Cells for Immunotherapy and for Gene and Drug Delivery |
| Q33856455 | Treatment of stress urinary incontinence with adipose tissue-derived stem cells |
| Q37572913 | Unexpected roles for bone marrow stromal cells (or MSCs): a real promise for cellular, but not replacement, therapy |
| Q37829108 | Using living cells to transport therapeutic genes for cancer treatment |
Search more.